Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 31
Biopharm constitutes 17% of Novo Nordisk sales and a
strategy has been defined to return to growth
DKK
billion
6
5
4
3
2
1
NovoSevenⓇ and Norditropin®
account for 84% of Biopharm sales¹
Other biopharmaceuticals
| Other haemophilia products
NorditropinⓇ
NovoSevenⓇ
'Return to Growth' strategy builds on organic,
non-organic and organisational initiatives
Return to
growth
in Biopharm
Drive in-market brands beyond
current plans and ensure
successful pipeline launches
Pursue licensing or acquisition of
complementary assets or
companies
Strengthen the organisation to
drive the Biopharm return to
growth agenda
0
Q4
2012
1 Reported sales for the full year 2017
changing
diabetes
Q4
2017
novo nordiskView entire presentation